JPH0570434B2 - - Google Patents
Info
- Publication number
- JPH0570434B2 JPH0570434B2 JP60225327A JP22532785A JPH0570434B2 JP H0570434 B2 JPH0570434 B2 JP H0570434B2 JP 60225327 A JP60225327 A JP 60225327A JP 22532785 A JP22532785 A JP 22532785A JP H0570434 B2 JPH0570434 B2 JP H0570434B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- lung adenocarcinoma
- human lung
- monoclonal antibody
- tissues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 46
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 46
- 208000020816 lung neoplasm Diseases 0.000 claims description 26
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 25
- 201000005202 lung cancer Diseases 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 210000004408 hybridoma Anatomy 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000003886 Glycoproteins Human genes 0.000 claims description 9
- 108090000288 Glycoproteins Proteins 0.000 claims description 9
- 229930186217 Glycolipid Natural products 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 5
- 238000011532 immunohistochemical staining Methods 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 239000012528 membrane Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 206010035226 Plasma cell myeloma Diseases 0.000 description 11
- 201000000050 myeloid neoplasm Diseases 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000009257 reactivity Effects 0.000 description 10
- 210000000628 antibody-producing cell Anatomy 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000007910 cell fusion Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000005348 Neuraminidase Human genes 0.000 description 5
- 108010006232 Neuraminidase Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 4
- 229960005508 8-azaguanine Drugs 0.000 description 4
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000872931 Myoporum sandwicense Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 2
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- QLNSPJMIYWEWNF-UHFFFAOYSA-N CC(C)CCCC(C)CCCC(C)CCCC(C)C.CC(C)CCCC(C)CCCC(C)CCCC(C)C Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C.CC(C)CCCC(C)CCCC(C)CCCC(C)C QLNSPJMIYWEWNF-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-UHFFFAOYSA-N azane;3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940031724 lung cancer vaccine Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
ç£æ¥äžã®å©çšåé
æ¬çºæã¯ãããèºçãç¹ã«ããèºè
ºçã«ç¹ç°æ§
ãæãããã®èªèããæåïŒãšãããŒãïŒãã·ã¢
ã«é žåãããç³ã¿ã³ãã¯ãããã¯ç³è質ã§ããã
ãšãç¹åŸŽãšããåã¯ããŒã³æ§æäœããã³ãã®èºè º
çã®ç ç蚺æãªãã³ã«è¡æž 蚺æã»ã¢ãã¿ãªã³ã°ãž
ã®å©çšã«é¢ãããã®ã§ããã åŸæ¥æè¡ æè¿ãå ç«åç©ããã®æäœç£ç现èãšéªšé«è «çŽ°
èãšãèåãããŠåŸããããã€ããªããŒããå¹é€
ããŠç¹ç°çã«è «çãšåå¿ããåã¯ããŒã³æ§æäœã
åŸãæ¹æ³ãå ±åãããŠãããããèºçã«å¯Ÿããå
ã¯ããŒã³æ§æäœããã®ãããªææ³ã§åŸãããšãã
ã§ã«å ±åãããŠããããã€ã³ãµãŒã»ãªãµãŒã
ïŒCancer Res.ïŒ42ïŒ150ïŒ1982ïŒããã€ã³ãµãŒã»ãª
ãµãŒãïŒCancer Res.ïŒ42ïŒ3187ïŒ1982ïŒããžã€ãŒ
ãã«ã»ãªãã»ãµãŒãžã«ã«ã»ãªãµãŒãïŒJ.Surgical
Res.ïŒïŒ30ïŒ403ïŒ1981ïŒããã©ã³ã¹ãã©ã³ããŒã·ãš
ã³ã»ããã·ã€ãŒãã€ã³ã°ïŒTransplantation
Proceed.ïŒïŒ(4)ïŒ1942ïŒ1981ïŒããžã€ãŒãã«ã»
ãªãã»ã€ã ãããžã€ïŒJ.lmmunol.ïŒïŒ131(1)497
ïŒ1983ïŒãå ç«åŠäŒèŠæšP.212ïŒæŒé¡çªå·107çªïŒ
ïŒ1983ïŒäº¬æ³èª ä¹ãããããããããã®åã¯ããŒã³
æ§æäœã®å€ãã¯ãèºç以å€ã®çããããæ£åžžçŽ°è
ãšãåå¿ãããã®ãã»ãšãã©èºçç¹ç°çãšããã
ãã®ã¯å°ãªãããŸããæ¯èŒçèºçã«ç¹ç°çãšãã
ããã®ããžã€ãŒãã«ã»ãªãã»ã€ã ãããžã€ïŒJ.
Immunol.ïŒ131(1) 497ïŒ1983ïŒãã§ããå°çŽ°èç
ãšéå°çŽ°èçãèå¥ããããšãã§ããã®ã¿ã§æå¹³
äžç®çãè «çãªã©ã®çµç¹åãå€å¥ããããšã¯ã§ã
ãªãããŸããèºçã®è¡æž 蚺æãžå¿çšã§ããåã¯ã
ãŒã³æ§æäœã«ã€ããŠã®å ±åã¯ãªãã æè¿ãæããæ¶ååšçïŒèçãèµçãå€§è žçïŒ
åã¯ããŒã³æ§æäœãçšããæ¶ååšçã®è¡æž 蚺æã
å ±åãããŠããããããã®åã¯ããŒã³æ§æäœã¯ã
ããããè¡æž äžæåãšããŠã·ã¢ã«é žåãããç³ã¿
ã³ãã¯ãèªèããŠãããã®ã§ããããžã€ãŒãã«ã»
ãªãã»ã¯ãªãã«ã«ã»ã€ã ãããžã€ïŒJ.Clin.
Immunol.ïŒïŒïŒïŒ135ïŒ1982ïŒïŒããšãã¬ãŒã·ãš
ã³ã»ããã·ã€ãŒ ãã€ã³ã°ã¹ïŒFederation
Proc.ïŒïŒ41ïŒ898ïŒ1982ïŒïŒãã€ã³ãµãŒã»ãªãµãŒã
ïŒCancer Res.ïŒïŒ42ïŒ601ïŒ1982ïŒïŒãã€ããªããŒ
ãïŒHybridomaïŒïŒïŒïŒ110ïŒ1983ïŒããäžæ¹ãèºç
ã«å¯Ÿããåã¯ããŒã³æ§æäœã§ãã·ã¢ã«é žåããã
ç³èçœè³ªãããã¯ç³è質ãèªèãããã®ã¯ãããŸ
ã§å šãå ±åããªãã çºæã解決ãã¹ãåé¡ç¹ããã³è§£æ±ºæ¹æ³ èºçã«ç¹ç°çã«åå¿ããåã¯ããŒã³æ§æäœãåŸ
ãããã°ãèºçã®èšºæã«æçšã§ãããèºçã®åã¯
ããŒã³æ§æäœã¯ç¥ãããŠããããã©ããããã«åª
ããæäœã®éçºãæãŸããŠãããæ¬çºæè ã¯ãã
èºè ºççµç¹èæåã§å ç«ããæäœç£çããŠã¹ã®èŸ
现èãšããŠã¹éªšé«è «çŽ°èãšãèåãããã€ããªã
ãŒããçç£ããã¢ãã¯ããŒãã«æäœããèºè «çã«
察ããŠç¹ã«åªããåå¿æ§ãæããèºçã®è¡æž 蚺æ
ã«å¿çšã§ããããšãèŠåºãæ¬çºæãå®æããã 以äžæ¬çºæã«ã€ããŠè©³çŽ°ã«èª¬æããã æ¬çºæã¯ãããèºè ºççµç¹èæåã§å ç«ããã
ãŠã¹ã®èŸçŽ°èãšããŠã¹éªšé«è «çŽ°èãšãèåãããŠ
ãã€ããªããŒããäœè£œããããèºè ºçã«ç¹ç°æ§ã
æããåã¯ããŒã³æ§æäœãéžæãã該ãã€ããªã
ãŒããå¹å°äžã«å¹é€ãããããŠã¹ã«æäžããŠè©²ã
ãŠã¹ã§è ¹æ°Žåãã該å¹é€ç©ãŸãã¯è ¹æ°Žããæ¡åã
ãããšã«ããåŸããããã€ã·ã¢ã«é žåãããç³è
çœè³ªãŸãã¯ç³è質ãæåãšããŠèªèããæããèº
è ºçç¹ç°çåã¯ããŒã³æ§æäœãæäŸããã æ¬çºæã®åã¯ããŒã³æ§æäœã¯ãIgMã¯ã©ã¹ã«å±
ããèºè «ç现èã«å¯ŸããŠç¹ç°çã«åå¿ããã·ã¢ã«
é žåãããç³èçœè³ªãŸãã¯ç³è質ãæåãšããŠèª
èããã æ¬çºæåã¯ããŒã³æ§æäœã®å ·äœäŸãšããŠã¯ãã
ã€ããªããŒã现èæ ªALCâ186ïŒNCACC
85082903ïŒãçç£ããALCâ186ããããããã 以äžã«æ¬çºæåã¯ããŒã³æ§æäœã®è£œé æ³ã詳现
ã«èª¬æããã (1) åç©ã®å ç«ãšæäœç£ç现èã®èª¿è£œ ïŒã10é±ä»€ãæãŸããã¯ïŒé±ä»€ã®ããŠã¹ã«ãã
ãèºè ºçã®çŽ°èãçµç¹ãããã¯ãããã®èæåã
å ç«ããŠããã®åç©ã®èŸããªã³ãç¯ãæ«æ¢¢è¡äžã®
æäœç£ç现èã調補ãããå ç«ããããŠã¹ã¯ãã
æ£åžžèºçŽ°èã§ååŠçããŠå ç«å¯å®¹ã«ããããŠã¹ã
çšããã®ã奜ãŸãããå ç«ã®æ¹æ³ã¯ãåç©ã®ç®äž
ãããã¯éèå ãããã¯è ¹è å ã«ãé©åœãªã¢ãžãŠ
ãã³ããäŸãã°ãããã€ã³ãã®å®å šã¢ãžãŠãã³ã
ïŒComplete Freundâ²s AdjuvantïŒãŸãã¯ãæ°Žé ž
åã¢ã«ãããŠã ã²ã«ãšçŸæ¥å³èã¯ã¯ãã³ãªã©ããš
ãšãã«ããèºè ºç现èïŒ106ã107现èïŒå¹ïŒãã
ãèºè ºççµç¹ãããã¯ãããã®èæåïŒèæçïŒ
ïŒ10ã500ÎŒgïŒå¹ïŒãæäžããã以åŸãïŒãïŒé±
éããã«ãæåãïŒãïŒåæäžãããåå ç«åŸïŒ
ãïŒæ¥ç®ã«çŒåºéèå¢ããæ¡è¡ãããã®è¡æž ãã
ãèºè ºçãšåå¿ããããšã以äžã«ç€ºãé µçŽ å ç«æž¬
å®æ³ãé µçŽ å ç«æž¬å®æ³ïŒELISAïŒïŒå»åŠæžé¢å
1976幎ããªã©ã§èª¿ã¹ãã é µçŽ å ç«æž¬å®æ³ïŒ 96ç©Žã®EIAçšãã¬ãŒãããããŒã»ã©ãã©ããªãŒ
ãºïŒFlow LaboratoriesïŒç€Ÿè£œãã«ãæ£åžžããã
ã¯è «ç现èãçµç¹ã®èæåïŒèçœéãšããŠ10ã
1000ÎŒgïŒmlå«æããèæçïŒã100ã200ÎŒïŒç©Ž
ãã€å泚ããïŒâã§ïŒãïŒæ©æŸçœ®ããŠãäžæž ãæ
ãå»ã€ãåŸãã¬ãžã³æ°Žãããã¯ãPBSïŒãªã³é žäº
ãããªãŠã 1.83ïœããªã³é žäžã«ãªãŠã 0.21ïœãé£
å¡©7.65ïœãèžæºæ°ŽïŒãPH7.2ïŒã§ããæŽæµåŸã
ïŒïŒ BSAïŒçè¡æž ã¢ã«ããã³ïŒâPBSã100ã200ÎŒ
ïŒç©Žå泚ããïŒâã§ïŒãïŒæ©æŸçœ®ããŠããã¬ãŒ
ãäžã«æ®ã€ãèçœè³ªãšã®çµåæ®åºããããã¯ïŒã
ãããã³ã°ïŒããããã®åŸãBSAâPBSãæšãŠã
ã¬ãžã³æ°Žãããã¯PBSã§ããæŽæµãåŸã第ïŒæ
äœãšããŠãBSAâPBSã§åžéããè©ŠæïŒããŠã¹
è¡æž ããã€ããªããŒãå¹é€ïŒ¡äžæž ãç²ç²Ÿè£œã¢ãã¯
ããŒãã«æäœïŒã100ÎŒïŒç©Žå泚ããïŒâã§ïŒ
æ©æŸçœ®ãããã¬ãžã³æ°Žã§ïŒåã2M NaCl溶液ã§
ïŒåæŽæµããåŸã第ïŒæäœãšããŠãŠãµã®ã®æããŠ
ã¹ã€ã ãã°ãããªã³IgGâãã«ãªãã·ããŒãŒçµå
ç©ããã³ïŒDAKOïŒç€Ÿè£œã販売å ååã¡ããã¯
ã¹ãã®100ååžé液ã100ÎŒïŒç©Žå泚ãã宀枩ã§
ïŒæéæŸçœ®ããã PBSã§ããæŽæµåŸãABTSåºè³ªæ¶²ãïŒïŒ2â²âã¢
ãžããã¹ïŒïŒâãšãã«ãã³ãŸãã¢ãŸãªã³âïŒâã¹
ã«ãã³é žïŒäºã¢ã³ã¢ããŠã 550mgã0.1Mã¯ãšã³é ž
ç·©è¡æ¶²ïŒPH4.2ïŒïŒã«æº¶ããã溶液ã«ã䜿çšçŽ
åã«éé žåæ°ŽçŽ 1ÎŒïŒmlãå ãã溶液ããçšãã
çºè²ãOD415onã®åžå 床ã§æž¬å®ããããã®ãšãã
èºè «ç现èãçµç¹ãããã¯ãããã®èæåã«å¯Ÿã
ãŠåŒ·ãåå¿ããããŠã¹ãããèºè ºçå ç«ããŠã¹ãš
ããŠãã€ããªããŒãäœè£œã®ããã®æäœç£ç现èã®
äŸçµŠæºãšããŠçšããã é µçŽ å ç«æž¬å®æ³ãè¡ãã«ããã€ãŠãæåãšã
ãŠã现èãã®ãã®ãçšããå Žåã¯ããã¢ã«ã³ã³
ïŒFalconïŒ3072ãã¬ãŒãäžã§ãæšç现èãå¹é€
ãã0.25ïŒ ã°ã«ã¿ãŒã«ã¢ã«ãããâPBSãå ãã
宀枩ã«ïŒãïŒæéæŸçœ®ããPBSã§ããæŽæµåŸã
ïŒïŒ BSAâPBS100ã200ÎŒãå ããïŒæéæŸçœ®
ããã¬ãžã³æ°ŽãŸãã¯PBSã§ããæŽæµãããã®ã
ã¬ãŒããçšããŠãäžè¬ã®æåã³ãŒããã¬ãŒããçš
ããã®ãšåæ§ã®æ¹æ³ã«ãŠãæäœäŸ¡ã®æž¬å®ãè¡ã€
ãã 现èèåã«äŸããã«ããã€ãŠãå ç«åããŠã¹ã«
èååŠçã®ïŒãïŒæ¥åã«ãããèºè ºç现èãçµç¹
ãããã¯ãã®èæåãïŒãïŒÃ106现èïŒå¹ãã
ãã¯20ã400ÎŒïŒå¹è å ã«æäžããèŸè现èã
æåºããèŸçŽ°èã調補ãããèŸèãMEMïŒæ¥æ°Ž
補è¬ç€Ÿè£œïŒäžã§çŽ°æãããã³ã»ããã§ã»ããã
1200rpmãïŒåéé å¿åé¢ã«ãããäžæž ãæšãŠã
ããªã¹âå¡©åã¢ã³ã¢ããŠã ç·©è¡æ¶²ïŒPH7.65ïŒã§ïŒ
ãïŒåéåŠçãèµ€è¡çãé€å»ããBMEMã§ïŒå
æŽæµããŠèåçšèŸçŽ°èãšããŠæäŸããã (2) 骚é«è «çŽ°èã®èª¿è£œ 骚é«è «çŽ°èãšããŠã¯ãããŠã¹ããåŸãããæ ªå
现èã䜿çšãããããšãã°ãïŒâã¢ã¶ã°ã¢ãã³è
æ§ããŠã¹ïŒBALBïŒïœç±æ¥ïŒéªšé«è «çŽ°èæ ªP3â
X63Ag8âU1ïŒP3âU1ïŒãã«ã¬ã³ãã»ãããã¯
ã¹ã»ã€ã³ã»ãã¯ããã€ãªããžã€ã»ã¢ã³ãã»ã€ã ã
ããžã€âïŒïŒCurent Topics in Microbiollogy
and ImmunologyâïŒïŒãããšãŒããã¢ã³ã»ãžã€ãŒ
ãã«ã»ãªãã»ã€ã ãããžã€ïŒEuropean J.
ImmunologyïŒïŒ 511â519ïŒ1976ïŒããSP2ïŒïŒ
âAg 14ïŒSPâïŒïŒããã€ãã€ãŒïŒNatureïŒ276ïŒ
269â270ïŒ1978ïŒããP3âX63âAg8653ïŒ653ïŒããž
ã€ãŒãã«ã»ãªãã»ã€ã ãããžã€ïŒJ.
ImmunologyïŒ123ïŒ1548â1550ïŒ1979ïŒããP3â
X63âAg8ïŒX63ïŒããã€ãã€ãŒïŒNaatureïŒ256ïŒ
äž495â497ïŒ1975ïŒããªã©ãçšããããããããã®
现èæ ªã¯ãïŒâã¢ã¶ã°ã¢ãã³å¹å°ãRPMlâ1640
å¹å°ã«ã°ã«ã¿ãã³ïŒ1.5mMïŒãïŒã¡ã«ã«ãããšã¿
ããŒã«ïŒïŒÃ10-5MïŒããžãšã³ã¿ãã€ã·ã³
ïŒ10ÎŒgïŒmlïŒããã³çèå è¡æž ïŒFCSïŒïŒCSL瀟
補ïŒïŒ10ïŒ ïŒãå ããæ£åžžå¹å°ã«ãããã«ïŒâã¢
ã¶ã°ã¢ãã³ïŒ15ÎŒïŒmlïŒãå ããå¹å°ãã§ç¶ä»£
ãããã现èèåã®ïŒãïŒæ¥åã«æ£åžžå¹å°ã«ç¶ä»£
ããèååœæ¥ïŒÃ107以äžã®çŽ°èæ°ã確ä¿ããã (3) 现èèå (1)ã§å ç«ããæäœç£ç现èãš(2)ã§åŸããã骚é«
è «çŽ°èãMEMå¹å°ãŸãã¯PBSã§ããæŽæµãã现
èæ°ããæäœç£ç现èïŒéªšé«è «çŽ°èïŒïŒã10ïŒïŒ
ã«ãªãããæ··åããé å¿åé¢ïŒ1200rpm5åïŒã
ãåŸãäžæž ãæšãŠãæ²æ®¿ãã现è矀ãããã»ãã
ãåŸãæ¹æããªããã37âã§ãããªãšãã¬ã³ã°ã©
ã€ã³ãŒã«1000ïŒPEGâ1000ïŒ2gãMEM2mlããã³
ãžã¡ãã«ã¹ã«ããã·ã0.7mlã®æ··æ¶²0.2ãïŒmlïŒ103
æäœç£ç现èãå ããïŒãïŒåéæ¯ã«MEM1ã
ïŒmlãæ°åå ããåŸãMEMãå ããŠå šéã50ml
ã«ãªãããã«ãããé å¿åé¢ïŒ900rp5åïŒåŸãäž
æž ãæšãŠãããããã«çŽ°èãã»ãããåŸãæ£åžžå¹
å°ïŒRPMI1640ãFCS10ïŒ 100mlãå ããã¡ã¹ã
ãããã«ããåžèŸŒã¿ãå¹åºãã§ããããã«çŽ°èã
æžæ¿ããã ãã®é¡æ¿æ¶²ã24ç©Žå¹é€çšãã¬ãŒãã«ïŒmlïŒç©Žã
ã€å泚ããïŒïŒ CO2ã€ã³ããŠããŒã¿ãŒäžã37âã§
24æéå¹é€ãããå¹é€ãã¬ãŒãã«ïŒmlïŒç©Žã®
HATå¹å°ãæ£åžžå¹å°ã«ããããµã³ãã³
ïŒ10-4MïŒããããžã³ïŒ1.5Ã10-5MïŒããã³ã¢ã
ããããªã³ïŒïŒÃ10-7MïŒãå ããå¹å°ããå
ããããã«24æéå¹é€ããã以åŸïŒæ¥éã24æé
æ¯ã«ãå¹é€äžæž ïŒmlãæšãŠãæ°ãã«åéã®HAT
å¹å°ãå ããCO2ã€ã³ããŠããŒã¿ãŒäžã37âã§10
ã14æ¥éå¹é€ããã ã³ãããŒç¶ã«çè²ããŠããèå现èã®èªããã
ãç©Žã«ã€ããŠãäžæž ïŒmlãæšãŠãHTå¹å°
ïŒHATå¹å°ããã¢ãããããªã³ãé€ããå¹å°ïŒ
ãåéå ãã以åŸïŒæ¥é24æéæ¯ã«HTå¹å°ãžã®
å€æãè¡ãã HTå¹å°ã§ïŒãïŒæ¥éå¹é€åŸãå¹é€äžæž ã®äžéš
ããšãäžèšã®é µçŽ å ç«æž¬å®æ³ã«ãããããèºè ºç
ã«å¯ŸããæäœäŸ¡ã枬å®ããããã®ãšããåæ§ã®æ¹
æ³ã§ãããæ£åžžçŽ°èãçµç¹ãããã¯ãã®èæåãª
ã©ãšã®åå¿æ§ã枬å®ããããèºè ºç现èçµç¹ãã
ãã¯ãã®èæåã«ç¹ç°çã«åå¿ãããã®ãéžæã
ããããèºè ºç现èãçµç¹ãããã¯ãã®èæåã«
匷ãåå¿ããããæ£åžžçŽ°èãçµç¹ãããã¯ãã®è
æåãªã©ã«åå¿ããªãç©Žã«ã€ããŠãéçåžéæ³ã«
ããã¯ããŒãã³ã°ãïŒåç¹°ãè¿ããå®å®ããŠãã
èºè ºç现èãçµç¹ãããã¯ãã®èæåã«åŒ·ãæäœ
䟡ã®èªãããããã®ãæããèºè ºçåã¯ããŒã³æ§
æäœç£çãã€ããªããŒãæ ªãšããŠéžæããã (4) åã¯ããŒã³æ§æäœã®èª¿è£œ ããªã¹ã¿ã³åŠçãïŒïŒïŒïŒ10ïŒ14âããã©ã¡ã
ã«ãã³ã¿ãã«ã³ïŒPristaneïŒ0.5mlãè ¹è å æäž
ããïŒé±é飌è²ãããããïŒã10é±ä»€ã®
BALBïŒïœéããŠã¹ã«ã(3)ã§åŸãããæããèº
è ºçåã¯ããŒã³æ§æäœç£çãã€ããªããŒã现èïŒ
ãïŒÃ106现èïŒå¹ãè ¹è å 泚å°ããã10ã21æ¥
ã§ãã€ããªããŒãã¯è ¹æ°Žçåããããã®ããŠã¹ã
ãè ¹æ°Žãæ¡åããé å¿åé¢ïŒ3000rpm ïŒåïŒã
ãŠåºåœ¢åãé€å»åŸã50ïŒ ç¡«é žã¢ã³ã¢ããŠã ã«ãŠå¡©
æããPBSã«NaCl0.5Mãå ãã液ã§éæããã»
ãã¢ã¯ãªã«S300ïŒãã¢ã«ãã·ã¢ã»ãã¢ã€ã³ã»ã±ã
ã«ã«ç€Ÿè£œïŒïŒãããããªãŠãŒã 750mlïŒã®ã«ã©ã ã«
æµé15mlïŒhrã§éå¡ããIgMç»åãéãã粟補å
ã¯ããŒã³æ§æäœãšããã æäœã®ã€ãœã¿ã€ãã®æ±ºå®ã¯ããªã¯ã¿ããã€
ïŒOuchterlonyïŒæ³ïŒäºéå ç«æ¡æ£æ³ïŒïŒå ç«åŠå®
éšå ¥éãçç©ååŠå®éšæ³15ãåŠäŒåºçã»ã³ã¿ãŒ
åãP.741981幎ïŒã«ãã€ãŠè¡ãã èçœéã®å®éã¯ãããªãŒãªã³æ³ããã³280nmã§
ã®åžå 床ã1.4ïŒOD280ïŒâã€ã ãã°ãããªã³ïŒ
mgïŒmlãããç®åºããã åŸãããåã¯ããŒã³æ§æäœã®ç¹ç°æ§ã®æ±ºå®ã¯è€
æ°ã®æ€äœããåŸãããããã®åçš®ã®èåšç±æ¥ã®æ£
åžžãããã¯è «ççµç¹ãããã¯ãã®èæåãšã®åå¿
æ§ãåçš®ããæ£åžžãããã¯è «ç现èå¹é€æ ªãŸãã¯
ããèå 现èå¹é€æ ªãããã¯ãããã®èæåãšã®
åå¿æ§ãåŸæ¥ããç¥ãããŠããçèå æ§æåïŒäŸ
ãã°CEAïŒãšã®åå¿æ§ãæ£åžžãæ£è ããè¡æž ãš
ã®åå¿æ§ãªã©ããé µçŽ å ç«æž¬å®æ³ãè¢å æäœæ³ã
å ç«çµç¹åŠçå€å®æ³ãïŒABCæ³ïŒãªã©ã«ããè¡
ãããããã®æž¬å®æ³ã«ãããŠãããèºè ºç以å€ãš
ã¯ãåå¿ããªããã®ãéžæããã ãŸãããã®ããã«ããŠåŸããããããèºè ºçã«
ç¹ç°çã«åå¿ããåã¯ããŒã³æ§æäœã¯ãè¡æž æ€
æ»ãçµç¹èšºæãã€ã¡ãŒãžâã³ã°ãªã©ã«ããèºçã®
蚺æãããã«ã¯ãæäœãã®ãã®ãããããã¯ãæ
äœã«å¶çå€ãæ¯çŽ ãçµåããããããããã€ã ã
ããã·ã³ãçæ£è ã«æäžããããšã«ããèºçã®æ²»
çãè¡ãããšãã§ãããã®ãšæåŸ ãããããã
ã«ããã®è «çç¹ç°çåã¯ããŒã³æ§æäœãçšããã¢
ãã€ããã€ãŒã«ã©ã ã«ãããè «çç¹ç°æåã粟補
ãããã®æåã®è§£æã²ããŠã¯ãèºçã¯ã¯ãã³ã®é
çºã«ã䜿çšã§ãããã®ãšæåŸ ãããã ïŒ èºçè¡æž 蚺ææ³ è¡æž 蚺æã¯æ¬¡ã®éãè¡ã 96ç©ŽEIAçšãã¬ãŒãã«ã第äžæäœ10ã100ÎŒgïŒ
mlã50ã200ÎŒïŒç©Žãã€å泚ããïŒâã§ïŒãïŒ
æ©ãããã¯ã宀枩ã§ïŒãïŒæéæŸçœ®ãããPBS
ã§æŽæµåŸãBSAâPBS200ÎŒïŒç©Žãå ãããã
ã«ïŒâã§ïŒæ©ãããã¯å®€æž©ã§ïŒæéæŸçœ®ãããã
ã®ãã¬ãŒããPBSã§ããæŽæµåŸãåç©Žã«è¡æž æ€
äœãïŒã100ååžéã§ã50ã100ÎŒãå ãããïŒ
âã§ïŒæ©ãããã¯å®€æž©ã§ïŒæéæŸçœ®åŸãPBSã§
ããæŽæµããã次ã«ãããªãã³åãã第äºæäœã
ããã¯ããã«ãªãã·ããŒãŒæšèãã第äºæäœïŒ10
ã100ÎŒgïŒÎŒïŒã50ã100ÎŒïŒç©Žå ããããã«
ïŒâã§ïŒæ©ãããã¯å®€æž©ã§ïŒãïŒæéæŸçœ®ããã
第äºæäœãšããŠãããªãã³åæäœã䜿çšããå Žå
ã«ã¯ããã¬ãŒããPBSã§ããæŽæµåŸãã¢ããžã³
âããªãã³âãã«ãªãã·ããŒãŒïŒ10ÎŒgïŒmlïŒã
50ã100ÎŒïŒç©Žå ãã宀枩ã§30åéæŸçœ®åŸPBS
ã§ããæŽæµããã次ã«åºè³ªæ¶²ãšããŠãABTSåº
質液ã50ã100ÎŒïŒç©Žå ãã宀枩ã§10ã30åé
æŸçœ®ããïŒïŒ SDS溶液50ã100ÎŒïŒç©Žãå ãå
å¿ãåæ¢ãããåç©Žã®OD415å€ã枬å®ãããã®çº
è²åºŠãããè¡æž æ€äœäžã®æåéãç®åºããããã®
ããã«ããŠåŸãããå¥åžžäººè¡æž äžã®æåéãšèºç
æ£è è¡æž äžã®æåéãæ¯èŒããããšã«ãããæ£åžž
å€ã決å®ãããã®æ£åžžå€ãè¶ ãããã®ãèºçéœæ§
ãšããã (6) æå解æ åè¿°ã®é µçŽ å ç«æäœæ³ãå ç«çµç¹ååŠçæè²æ³
ãããã¯è¡æž 蚺ææ³ã®å®æœã«éããŠãæåïŒèºè º
çèæåãèºçå¹é€çŽ°èæ ªãèºççµç¹ïŒããã€ã©
ããããŒãŒïŒneuraminidaseïŒããããã¢ãŒãŒ
ïŒproteaseïŒãªã©ã®é µçŽ ãéãšãŠçŽ é žãªã©ã®è©Šè¬
ã§ååŠçããåŸãåã¯ããŒã³æ§æäœãšåå¿ããã
ãããã®åŠçãããŠããªãå ã®æåãšåã¯ããŒã³
æ§æäœã®åå¿æ§ãšã®å·®ãããæåã®ååŠçæ§ç¶
ïŒåã¯ããŒã³æ§æäœã®èªèããæåéšäœã®ååŠç
æ§ç¶ïŒãæããã«ãããããªãã¡ããã€ã©ããã
ãŒãŒåŠçã«ããæåæ§ãæ¶å€±ããã°ãã·ã¢ã«é ž
ãããããã¢ãŒãŒåŠçã«ããæ¶å€±ããã°èçœè³ª
ãããŸãéãšãŠçŽ é žåŠçã«ããæ¶å€±ããã°ç³é
ããæå決å®åºã«é¢äžããŠãããšæšå®ãããã 以äžæ¬çºæã®å®æœäŸã瀺ãã å®æœäŸ ïŒ (1) æäœç£ç现èã®èª¿è£œ ããæ£åžžèºçµç¹èæåïŒïŒmgèçœè³ªïŒå¹ïŒãã
çåŸ24æé以å ã®æ°çä»BALBïŒïœããŠã¹ã«é
èå æäžãããïŒé±éçµéåŸã®ããŠã¹ã«ããèºè º
çèæç100ÎŒïŒèçœè³ªæç®ïŒïŒå¹ãæ°Žé žåã¢
ã«ãããŠã ã²ã«ïŒmgïŒå¹ãçŸæ¥å³èæ»èã¯ã¯ãã³
ïŒÃ109ïŒå¹ãšãšãã«è ¹è å æäžããã以åŸïŒã
ïŒé±ããã«ãåäžæå100ÎŒgïŒèçœè³ªæç®ïŒïŒå¹
ã§ïŒãïŒåå ç«ããããããå ç«åŠçããããŠã¹
ã®ãã¡ããã®æè¡æž ããããèºè ºç现èãŸãã¯çµ
ç¹ãããã¯ãããã®èæçãšåŒ·ãåå¿ããããŠã¹
ãå ç«ããŠã¹ãšããŠããã®ããŠã¹ãããèŸçŽ°èã
調補ããŠã现èèåã«äŸããã (2) ããŠã¹éªšé«è «çŽ°èã®èª¿è£œ ïŒâã¢ã¶ã°ã¢ãã³èæ§ããŠã¹éªšé«è «çŽ°èæ ªP3
âU1ãæ£åžžå¹å°ã§å¹é€ãã现èèåæã«ïŒÃ107
以äžã®çŽ°èãåŸã现èèåã«èŠªæ ªãšããŠäŸããã (3) ãã€ããªããŒãã®äœè£œ (1)ãš(2)ã§åŸãããèŸçŽ°èãšéªšé«è «çŽ°èãšãïŒïŒ
ïŒã®å²åã§çšããåè¿°ããæ¹åŒã§èåããã
HATå¹å°ã§37âã14æ¥éCO25ïŒ ä»¥äžã§å¹é€ã
ããèå现èãéžæããHTå¹å°ã«å€ããŠããã«
å¹é€ããæããèºè ºçã«å¯ŸããæäœäŸ¡ã®æž¬å®ãã
ãŠã掻æ§ãªç©Žãéžã³ãããã«æ£åžžå¹å°ã«å€ããïŒ
åã¯ããŒãã³ã°ãç¹°ãè¿ããŠãçš®ã ã®æž¬å®æ³ã«ã
ããããæ£åžžçŽ°èãçµç¹ãããã¯ä»ã®çã«å šãå
å¿ãããããèºè ºçã«ç¹ç°çã«åå¿ããåã¯ããŒ
ã³æ§æäœãç£çãããã€ããªããŒãæ ªALCâ186
ãéžæããã ïŒ åã¯ããŒã³æ§æäœã®ç²Ÿè£œ ããªã¹ã¿ã³åŠçããïŒé±ä»€BALBïŒïœéããŠ
ã¹ã«(3)ã§åŸããããã€ããªããŒãæ ªALCâ186ã
ïŒÃ106现èïŒå¹è ¹è å 泚å°ããã10ã21æ¥åŸã«ã
ãã€ããªããŒãã¯è ¹æ°Žçåãããè ¹æ°Žã®ããŸã€ã
ããŠã¹ãããè ¹æ°Žãæ¡åïŒïŒã10mlïŒå¹ïŒããé
å¿åé¢ïŒ3000rpmïŒïŒåïŒããŠåºåœ¢åãé€å»ã
ãã50ïŒ ç¡«é žã¢ã³ã¢ããŠã ã«ãŠå¡©æããPBSã«
NaCl 0.5Mãå ãã液ã§éæããã»ãã¢ã¯ãªã«
S300ïŒãã¢ã«ãã·ã¢ã»ãã¢ã€ã³ã»ã±ãã«ã«ç€Ÿè£œïŒ
ïŒãããã»ããªãŠãŒã 750mlïŒã®ã«ã©ã ã«æµé15
mlïŒhrã§éå¡ãIgMç»åãéã粟補æäœãšããŠçš
ããã (5) ALCâ186ã®ç¹ç°æ§ ãã®ããã«ããŠåŸãããæèºè ºçç¹ç°çåã¯ã
ãŒã³æ§æäœALCâ186ã®åå¿ç¹ç°æ§ã第ïŒè¡šã«ç€º
ããã
ãæãããã®èªèããæåïŒãšãããŒãïŒãã·ã¢
ã«é žåãããç³ã¿ã³ãã¯ãããã¯ç³è質ã§ããã
ãšãç¹åŸŽãšããåã¯ããŒã³æ§æäœããã³ãã®èºè º
çã®ç ç蚺æãªãã³ã«è¡æž 蚺æã»ã¢ãã¿ãªã³ã°ãž
ã®å©çšã«é¢ãããã®ã§ããã åŸæ¥æè¡ æè¿ãå ç«åç©ããã®æäœç£ç现èãšéªšé«è «çŽ°
èãšãèåãããŠåŸããããã€ããªããŒããå¹é€
ããŠç¹ç°çã«è «çãšåå¿ããåã¯ããŒã³æ§æäœã
åŸãæ¹æ³ãå ±åãããŠãããããèºçã«å¯Ÿããå
ã¯ããŒã³æ§æäœããã®ãããªææ³ã§åŸãããšãã
ã§ã«å ±åãããŠããããã€ã³ãµãŒã»ãªãµãŒã
ïŒCancer Res.ïŒ42ïŒ150ïŒ1982ïŒããã€ã³ãµãŒã»ãª
ãµãŒãïŒCancer Res.ïŒ42ïŒ3187ïŒ1982ïŒããžã€ãŒ
ãã«ã»ãªãã»ãµãŒãžã«ã«ã»ãªãµãŒãïŒJ.Surgical
Res.ïŒïŒ30ïŒ403ïŒ1981ïŒããã©ã³ã¹ãã©ã³ããŒã·ãš
ã³ã»ããã·ã€ãŒãã€ã³ã°ïŒTransplantation
Proceed.ïŒïŒ(4)ïŒ1942ïŒ1981ïŒããžã€ãŒãã«ã»
ãªãã»ã€ã ãããžã€ïŒJ.lmmunol.ïŒïŒ131(1)497
ïŒ1983ïŒãå ç«åŠäŒèŠæšP.212ïŒæŒé¡çªå·107çªïŒ
ïŒ1983ïŒäº¬æ³èª ä¹ãããããããããã®åã¯ããŒã³
æ§æäœã®å€ãã¯ãèºç以å€ã®çããããæ£åžžçŽ°è
ãšãåå¿ãããã®ãã»ãšãã©èºçç¹ç°çãšããã
ãã®ã¯å°ãªãããŸããæ¯èŒçèºçã«ç¹ç°çãšãã
ããã®ããžã€ãŒãã«ã»ãªãã»ã€ã ãããžã€ïŒJ.
Immunol.ïŒ131(1) 497ïŒ1983ïŒãã§ããå°çŽ°èç
ãšéå°çŽ°èçãèå¥ããããšãã§ããã®ã¿ã§æå¹³
äžç®çãè «çãªã©ã®çµç¹åãå€å¥ããããšã¯ã§ã
ãªãããŸããèºçã®è¡æž 蚺æãžå¿çšã§ããåã¯ã
ãŒã³æ§æäœã«ã€ããŠã®å ±åã¯ãªãã æè¿ãæããæ¶ååšçïŒèçãèµçãå€§è žçïŒ
åã¯ããŒã³æ§æäœãçšããæ¶ååšçã®è¡æž 蚺æã
å ±åãããŠããããããã®åã¯ããŒã³æ§æäœã¯ã
ããããè¡æž äžæåãšããŠã·ã¢ã«é žåãããç³ã¿
ã³ãã¯ãèªèããŠãããã®ã§ããããžã€ãŒãã«ã»
ãªãã»ã¯ãªãã«ã«ã»ã€ã ãããžã€ïŒJ.Clin.
Immunol.ïŒïŒïŒïŒ135ïŒ1982ïŒïŒããšãã¬ãŒã·ãš
ã³ã»ããã·ã€ãŒ ãã€ã³ã°ã¹ïŒFederation
Proc.ïŒïŒ41ïŒ898ïŒ1982ïŒïŒãã€ã³ãµãŒã»ãªãµãŒã
ïŒCancer Res.ïŒïŒ42ïŒ601ïŒ1982ïŒïŒãã€ããªããŒ
ãïŒHybridomaïŒïŒïŒïŒ110ïŒ1983ïŒããäžæ¹ãèºç
ã«å¯Ÿããåã¯ããŒã³æ§æäœã§ãã·ã¢ã«é žåããã
ç³èçœè³ªãããã¯ç³è質ãèªèãããã®ã¯ãããŸ
ã§å šãå ±åããªãã çºæã解決ãã¹ãåé¡ç¹ããã³è§£æ±ºæ¹æ³ èºçã«ç¹ç°çã«åå¿ããåã¯ããŒã³æ§æäœãåŸ
ãããã°ãèºçã®èšºæã«æçšã§ãããèºçã®åã¯
ããŒã³æ§æäœã¯ç¥ãããŠããããã©ããããã«åª
ããæäœã®éçºãæãŸããŠãããæ¬çºæè ã¯ãã
èºè ºççµç¹èæåã§å ç«ããæäœç£çããŠã¹ã®èŸ
现èãšããŠã¹éªšé«è «çŽ°èãšãèåãããã€ããªã
ãŒããçç£ããã¢ãã¯ããŒãã«æäœããèºè «çã«
察ããŠç¹ã«åªããåå¿æ§ãæããèºçã®è¡æž 蚺æ
ã«å¿çšã§ããããšãèŠåºãæ¬çºæãå®æããã 以äžæ¬çºæã«ã€ããŠè©³çŽ°ã«èª¬æããã æ¬çºæã¯ãããèºè ºççµç¹èæåã§å ç«ããã
ãŠã¹ã®èŸçŽ°èãšããŠã¹éªšé«è «çŽ°èãšãèåãããŠ
ãã€ããªããŒããäœè£œããããèºè ºçã«ç¹ç°æ§ã
æããåã¯ããŒã³æ§æäœãéžæãã該ãã€ããªã
ãŒããå¹å°äžã«å¹é€ãããããŠã¹ã«æäžããŠè©²ã
ãŠã¹ã§è ¹æ°Žåãã該å¹é€ç©ãŸãã¯è ¹æ°Žããæ¡åã
ãããšã«ããåŸããããã€ã·ã¢ã«é žåãããç³è
çœè³ªãŸãã¯ç³è質ãæåãšããŠèªèããæããèº
è ºçç¹ç°çåã¯ããŒã³æ§æäœãæäŸããã æ¬çºæã®åã¯ããŒã³æ§æäœã¯ãIgMã¯ã©ã¹ã«å±
ããèºè «ç现èã«å¯ŸããŠç¹ç°çã«åå¿ããã·ã¢ã«
é žåãããç³èçœè³ªãŸãã¯ç³è質ãæåãšããŠèª
èããã æ¬çºæåã¯ããŒã³æ§æäœã®å ·äœäŸãšããŠã¯ãã
ã€ããªããŒã现èæ ªALCâ186ïŒNCACC
85082903ïŒãçç£ããALCâ186ããããããã 以äžã«æ¬çºæåã¯ããŒã³æ§æäœã®è£œé æ³ã詳现
ã«èª¬æããã (1) åç©ã®å ç«ãšæäœç£ç现èã®èª¿è£œ ïŒã10é±ä»€ãæãŸããã¯ïŒé±ä»€ã®ããŠã¹ã«ãã
ãèºè ºçã®çŽ°èãçµç¹ãããã¯ãããã®èæåã
å ç«ããŠããã®åç©ã®èŸããªã³ãç¯ãæ«æ¢¢è¡äžã®
æäœç£ç现èã調補ãããå ç«ããããŠã¹ã¯ãã
æ£åžžèºçŽ°èã§ååŠçããŠå ç«å¯å®¹ã«ããããŠã¹ã
çšããã®ã奜ãŸãããå ç«ã®æ¹æ³ã¯ãåç©ã®ç®äž
ãããã¯éèå ãããã¯è ¹è å ã«ãé©åœãªã¢ãžãŠ
ãã³ããäŸãã°ãããã€ã³ãã®å®å šã¢ãžãŠãã³ã
ïŒComplete Freundâ²s AdjuvantïŒãŸãã¯ãæ°Žé ž
åã¢ã«ãããŠã ã²ã«ãšçŸæ¥å³èã¯ã¯ãã³ãªã©ããš
ãšãã«ããèºè ºç现èïŒ106ã107现èïŒå¹ïŒãã
ãèºè ºççµç¹ãããã¯ãããã®èæåïŒèæçïŒ
ïŒ10ã500ÎŒgïŒå¹ïŒãæäžããã以åŸãïŒãïŒé±
éããã«ãæåãïŒãïŒåæäžãããåå ç«åŸïŒ
ãïŒæ¥ç®ã«çŒåºéèå¢ããæ¡è¡ãããã®è¡æž ãã
ãèºè ºçãšåå¿ããããšã以äžã«ç€ºãé µçŽ å ç«æž¬
å®æ³ãé µçŽ å ç«æž¬å®æ³ïŒELISAïŒïŒå»åŠæžé¢å
1976幎ããªã©ã§èª¿ã¹ãã é µçŽ å ç«æž¬å®æ³ïŒ 96ç©Žã®EIAçšãã¬ãŒãããããŒã»ã©ãã©ããªãŒ
ãºïŒFlow LaboratoriesïŒç€Ÿè£œãã«ãæ£åžžããã
ã¯è «ç现èãçµç¹ã®èæåïŒèçœéãšããŠ10ã
1000ÎŒgïŒmlå«æããèæçïŒã100ã200ÎŒïŒç©Ž
ãã€å泚ããïŒâã§ïŒãïŒæ©æŸçœ®ããŠãäžæž ãæ
ãå»ã€ãåŸãã¬ãžã³æ°Žãããã¯ãPBSïŒãªã³é žäº
ãããªãŠã 1.83ïœããªã³é žäžã«ãªãŠã 0.21ïœãé£
å¡©7.65ïœãèžæºæ°ŽïŒãPH7.2ïŒã§ããæŽæµåŸã
ïŒïŒ BSAïŒçè¡æž ã¢ã«ããã³ïŒâPBSã100ã200ÎŒ
ïŒç©Žå泚ããïŒâã§ïŒãïŒæ©æŸçœ®ããŠããã¬ãŒ
ãäžã«æ®ã€ãèçœè³ªãšã®çµåæ®åºããããã¯ïŒã
ãããã³ã°ïŒããããã®åŸãBSAâPBSãæšãŠã
ã¬ãžã³æ°Žãããã¯PBSã§ããæŽæµãåŸã第ïŒæ
äœãšããŠãBSAâPBSã§åžéããè©ŠæïŒããŠã¹
è¡æž ããã€ããªããŒãå¹é€ïŒ¡äžæž ãç²ç²Ÿè£œã¢ãã¯
ããŒãã«æäœïŒã100ÎŒïŒç©Žå泚ããïŒâã§ïŒ
æ©æŸçœ®ãããã¬ãžã³æ°Žã§ïŒåã2M NaCl溶液ã§
ïŒåæŽæµããåŸã第ïŒæäœãšããŠãŠãµã®ã®æããŠ
ã¹ã€ã ãã°ãããªã³IgGâãã«ãªãã·ããŒãŒçµå
ç©ããã³ïŒDAKOïŒç€Ÿè£œã販売å ååã¡ããã¯
ã¹ãã®100ååžé液ã100ÎŒïŒç©Žå泚ãã宀枩ã§
ïŒæéæŸçœ®ããã PBSã§ããæŽæµåŸãABTSåºè³ªæ¶²ãïŒïŒ2â²âã¢
ãžããã¹ïŒïŒâãšãã«ãã³ãŸãã¢ãŸãªã³âïŒâã¹
ã«ãã³é žïŒäºã¢ã³ã¢ããŠã 550mgã0.1Mã¯ãšã³é ž
ç·©è¡æ¶²ïŒPH4.2ïŒïŒã«æº¶ããã溶液ã«ã䜿çšçŽ
åã«éé žåæ°ŽçŽ 1ÎŒïŒmlãå ãã溶液ããçšãã
çºè²ãOD415onã®åžå 床ã§æž¬å®ããããã®ãšãã
èºè «ç现èãçµç¹ãããã¯ãããã®èæåã«å¯Ÿã
ãŠåŒ·ãåå¿ããããŠã¹ãããèºè ºçå ç«ããŠã¹ãš
ããŠãã€ããªããŒãäœè£œã®ããã®æäœç£ç现èã®
äŸçµŠæºãšããŠçšããã é µçŽ å ç«æž¬å®æ³ãè¡ãã«ããã€ãŠãæåãšã
ãŠã现èãã®ãã®ãçšããå Žåã¯ããã¢ã«ã³ã³
ïŒFalconïŒ3072ãã¬ãŒãäžã§ãæšç现èãå¹é€
ãã0.25ïŒ ã°ã«ã¿ãŒã«ã¢ã«ãããâPBSãå ãã
宀枩ã«ïŒãïŒæéæŸçœ®ããPBSã§ããæŽæµåŸã
ïŒïŒ BSAâPBS100ã200ÎŒãå ããïŒæéæŸçœ®
ããã¬ãžã³æ°ŽãŸãã¯PBSã§ããæŽæµãããã®ã
ã¬ãŒããçšããŠãäžè¬ã®æåã³ãŒããã¬ãŒããçš
ããã®ãšåæ§ã®æ¹æ³ã«ãŠãæäœäŸ¡ã®æž¬å®ãè¡ã€
ãã 现èèåã«äŸããã«ããã€ãŠãå ç«åããŠã¹ã«
èååŠçã®ïŒãïŒæ¥åã«ãããèºè ºç现èãçµç¹
ãããã¯ãã®èæåãïŒãïŒÃ106现èïŒå¹ãã
ãã¯20ã400ÎŒïŒå¹è å ã«æäžããèŸè现èã
æåºããèŸçŽ°èã調補ãããèŸèãMEMïŒæ¥æ°Ž
補è¬ç€Ÿè£œïŒäžã§çŽ°æãããã³ã»ããã§ã»ããã
1200rpmãïŒåéé å¿åé¢ã«ãããäžæž ãæšãŠã
ããªã¹âå¡©åã¢ã³ã¢ããŠã ç·©è¡æ¶²ïŒPH7.65ïŒã§ïŒ
ãïŒåéåŠçãèµ€è¡çãé€å»ããBMEMã§ïŒå
æŽæµããŠèåçšèŸçŽ°èãšããŠæäŸããã (2) 骚é«è «çŽ°èã®èª¿è£œ 骚é«è «çŽ°èãšããŠã¯ãããŠã¹ããåŸãããæ ªå
现èã䜿çšãããããšãã°ãïŒâã¢ã¶ã°ã¢ãã³è
æ§ããŠã¹ïŒBALBïŒïœç±æ¥ïŒéªšé«è «çŽ°èæ ªP3â
X63Ag8âU1ïŒP3âU1ïŒãã«ã¬ã³ãã»ãããã¯
ã¹ã»ã€ã³ã»ãã¯ããã€ãªããžã€ã»ã¢ã³ãã»ã€ã ã
ããžã€âïŒïŒCurent Topics in Microbiollogy
and ImmunologyâïŒïŒãããšãŒããã¢ã³ã»ãžã€ãŒ
ãã«ã»ãªãã»ã€ã ãããžã€ïŒEuropean J.
ImmunologyïŒïŒ 511â519ïŒ1976ïŒããSP2ïŒïŒ
âAg 14ïŒSPâïŒïŒããã€ãã€ãŒïŒNatureïŒ276ïŒ
269â270ïŒ1978ïŒããP3âX63âAg8653ïŒ653ïŒããž
ã€ãŒãã«ã»ãªãã»ã€ã ãããžã€ïŒJ.
ImmunologyïŒ123ïŒ1548â1550ïŒ1979ïŒããP3â
X63âAg8ïŒX63ïŒããã€ãã€ãŒïŒNaatureïŒ256ïŒ
äž495â497ïŒ1975ïŒããªã©ãçšããããããããã®
现èæ ªã¯ãïŒâã¢ã¶ã°ã¢ãã³å¹å°ãRPMlâ1640
å¹å°ã«ã°ã«ã¿ãã³ïŒ1.5mMïŒãïŒã¡ã«ã«ãããšã¿
ããŒã«ïŒïŒÃ10-5MïŒããžãšã³ã¿ãã€ã·ã³
ïŒ10ÎŒgïŒmlïŒããã³çèå è¡æž ïŒFCSïŒïŒCSL瀟
補ïŒïŒ10ïŒ ïŒãå ããæ£åžžå¹å°ã«ãããã«ïŒâã¢
ã¶ã°ã¢ãã³ïŒ15ÎŒïŒmlïŒãå ããå¹å°ãã§ç¶ä»£
ãããã现èèåã®ïŒãïŒæ¥åã«æ£åžžå¹å°ã«ç¶ä»£
ããèååœæ¥ïŒÃ107以äžã®çŽ°èæ°ã確ä¿ããã (3) 现èèå (1)ã§å ç«ããæäœç£ç现èãš(2)ã§åŸããã骚é«
è «çŽ°èãMEMå¹å°ãŸãã¯PBSã§ããæŽæµãã现
èæ°ããæäœç£ç现èïŒéªšé«è «çŽ°èïŒïŒã10ïŒïŒ
ã«ãªãããæ··åããé å¿åé¢ïŒ1200rpm5åïŒã
ãåŸãäžæž ãæšãŠãæ²æ®¿ãã现è矀ãããã»ãã
ãåŸãæ¹æããªããã37âã§ãããªãšãã¬ã³ã°ã©
ã€ã³ãŒã«1000ïŒPEGâ1000ïŒ2gãMEM2mlããã³
ãžã¡ãã«ã¹ã«ããã·ã0.7mlã®æ··æ¶²0.2ãïŒmlïŒ103
æäœç£ç现èãå ããïŒãïŒåéæ¯ã«MEM1ã
ïŒmlãæ°åå ããåŸãMEMãå ããŠå šéã50ml
ã«ãªãããã«ãããé å¿åé¢ïŒ900rp5åïŒåŸãäž
æž ãæšãŠãããããã«çŽ°èãã»ãããåŸãæ£åžžå¹
å°ïŒRPMI1640ãFCS10ïŒ 100mlãå ããã¡ã¹ã
ãããã«ããåžèŸŒã¿ãå¹åºãã§ããããã«çŽ°èã
æžæ¿ããã ãã®é¡æ¿æ¶²ã24ç©Žå¹é€çšãã¬ãŒãã«ïŒmlïŒç©Žã
ã€å泚ããïŒïŒ CO2ã€ã³ããŠããŒã¿ãŒäžã37âã§
24æéå¹é€ãããå¹é€ãã¬ãŒãã«ïŒmlïŒç©Žã®
HATå¹å°ãæ£åžžå¹å°ã«ããããµã³ãã³
ïŒ10-4MïŒããããžã³ïŒ1.5Ã10-5MïŒããã³ã¢ã
ããããªã³ïŒïŒÃ10-7MïŒãå ããå¹å°ããå
ããããã«24æéå¹é€ããã以åŸïŒæ¥éã24æé
æ¯ã«ãå¹é€äžæž ïŒmlãæšãŠãæ°ãã«åéã®HAT
å¹å°ãå ããCO2ã€ã³ããŠããŒã¿ãŒäžã37âã§10
ã14æ¥éå¹é€ããã ã³ãããŒç¶ã«çè²ããŠããèå现èã®èªããã
ãç©Žã«ã€ããŠãäžæž ïŒmlãæšãŠãHTå¹å°
ïŒHATå¹å°ããã¢ãããããªã³ãé€ããå¹å°ïŒ
ãåéå ãã以åŸïŒæ¥é24æéæ¯ã«HTå¹å°ãžã®
å€æãè¡ãã HTå¹å°ã§ïŒãïŒæ¥éå¹é€åŸãå¹é€äžæž ã®äžéš
ããšãäžèšã®é µçŽ å ç«æž¬å®æ³ã«ãããããèºè ºç
ã«å¯ŸããæäœäŸ¡ã枬å®ããããã®ãšããåæ§ã®æ¹
æ³ã§ãããæ£åžžçŽ°èãçµç¹ãããã¯ãã®èæåãª
ã©ãšã®åå¿æ§ã枬å®ããããèºè ºç现èçµç¹ãã
ãã¯ãã®èæåã«ç¹ç°çã«åå¿ãããã®ãéžæã
ããããèºè ºç现èãçµç¹ãããã¯ãã®èæåã«
匷ãåå¿ããããæ£åžžçŽ°èãçµç¹ãããã¯ãã®è
æåãªã©ã«åå¿ããªãç©Žã«ã€ããŠãéçåžéæ³ã«
ããã¯ããŒãã³ã°ãïŒåç¹°ãè¿ããå®å®ããŠãã
èºè ºç现èãçµç¹ãããã¯ãã®èæåã«åŒ·ãæäœ
䟡ã®èªãããããã®ãæããèºè ºçåã¯ããŒã³æ§
æäœç£çãã€ããªããŒãæ ªãšããŠéžæããã (4) åã¯ããŒã³æ§æäœã®èª¿è£œ ããªã¹ã¿ã³åŠçãïŒïŒïŒïŒ10ïŒ14âããã©ã¡ã
ã«ãã³ã¿ãã«ã³ïŒPristaneïŒ0.5mlãè ¹è å æäž
ããïŒé±é飌è²ãããããïŒã10é±ä»€ã®
BALBïŒïœéããŠã¹ã«ã(3)ã§åŸãããæããèº
è ºçåã¯ããŒã³æ§æäœç£çãã€ããªããŒã现èïŒ
ãïŒÃ106现èïŒå¹ãè ¹è å 泚å°ããã10ã21æ¥
ã§ãã€ããªããŒãã¯è ¹æ°Žçåããããã®ããŠã¹ã
ãè ¹æ°Žãæ¡åããé å¿åé¢ïŒ3000rpm ïŒåïŒã
ãŠåºåœ¢åãé€å»åŸã50ïŒ ç¡«é žã¢ã³ã¢ããŠã ã«ãŠå¡©
æããPBSã«NaCl0.5Mãå ãã液ã§éæããã»
ãã¢ã¯ãªã«S300ïŒãã¢ã«ãã·ã¢ã»ãã¢ã€ã³ã»ã±ã
ã«ã«ç€Ÿè£œïŒïŒãããããªãŠãŒã 750mlïŒã®ã«ã©ã ã«
æµé15mlïŒhrã§éå¡ããIgMç»åãéãã粟補å
ã¯ããŒã³æ§æäœãšããã æäœã®ã€ãœã¿ã€ãã®æ±ºå®ã¯ããªã¯ã¿ããã€
ïŒOuchterlonyïŒæ³ïŒäºéå ç«æ¡æ£æ³ïŒïŒå ç«åŠå®
éšå ¥éãçç©ååŠå®éšæ³15ãåŠäŒåºçã»ã³ã¿ãŒ
åãP.741981幎ïŒã«ãã€ãŠè¡ãã èçœéã®å®éã¯ãããªãŒãªã³æ³ããã³280nmã§
ã®åžå 床ã1.4ïŒOD280ïŒâã€ã ãã°ãããªã³ïŒ
mgïŒmlãããç®åºããã åŸãããåã¯ããŒã³æ§æäœã®ç¹ç°æ§ã®æ±ºå®ã¯è€
æ°ã®æ€äœããåŸãããããã®åçš®ã®èåšç±æ¥ã®æ£
åžžãããã¯è «ççµç¹ãããã¯ãã®èæåãšã®åå¿
æ§ãåçš®ããæ£åžžãããã¯è «ç现èå¹é€æ ªãŸãã¯
ããèå 现èå¹é€æ ªãããã¯ãããã®èæåãšã®
åå¿æ§ãåŸæ¥ããç¥ãããŠããçèå æ§æåïŒäŸ
ãã°CEAïŒãšã®åå¿æ§ãæ£åžžãæ£è ããè¡æž ãš
ã®åå¿æ§ãªã©ããé µçŽ å ç«æž¬å®æ³ãè¢å æäœæ³ã
å ç«çµç¹åŠçå€å®æ³ãïŒABCæ³ïŒãªã©ã«ããè¡
ãããããã®æž¬å®æ³ã«ãããŠãããèºè ºç以å€ãš
ã¯ãåå¿ããªããã®ãéžæããã ãŸãããã®ããã«ããŠåŸããããããèºè ºçã«
ç¹ç°çã«åå¿ããåã¯ããŒã³æ§æäœã¯ãè¡æž æ€
æ»ãçµç¹èšºæãã€ã¡ãŒãžâã³ã°ãªã©ã«ããèºçã®
蚺æãããã«ã¯ãæäœãã®ãã®ãããããã¯ãæ
äœã«å¶çå€ãæ¯çŽ ãçµåããããããããã€ã ã
ããã·ã³ãçæ£è ã«æäžããããšã«ããèºçã®æ²»
çãè¡ãããšãã§ãããã®ãšæåŸ ãããããã
ã«ããã®è «çç¹ç°çåã¯ããŒã³æ§æäœãçšããã¢
ãã€ããã€ãŒã«ã©ã ã«ãããè «çç¹ç°æåã粟補
ãããã®æåã®è§£æã²ããŠã¯ãèºçã¯ã¯ãã³ã®é
çºã«ã䜿çšã§ãããã®ãšæåŸ ãããã ïŒ èºçè¡æž 蚺ææ³ è¡æž 蚺æã¯æ¬¡ã®éãè¡ã 96ç©ŽEIAçšãã¬ãŒãã«ã第äžæäœ10ã100ÎŒgïŒ
mlã50ã200ÎŒïŒç©Žãã€å泚ããïŒâã§ïŒãïŒ
æ©ãããã¯ã宀枩ã§ïŒãïŒæéæŸçœ®ãããPBS
ã§æŽæµåŸãBSAâPBS200ÎŒïŒç©Žãå ãããã
ã«ïŒâã§ïŒæ©ãããã¯å®€æž©ã§ïŒæéæŸçœ®ãããã
ã®ãã¬ãŒããPBSã§ããæŽæµåŸãåç©Žã«è¡æž æ€
äœãïŒã100ååžéã§ã50ã100ÎŒãå ãããïŒ
âã§ïŒæ©ãããã¯å®€æž©ã§ïŒæéæŸçœ®åŸãPBSã§
ããæŽæµããã次ã«ãããªãã³åãã第äºæäœã
ããã¯ããã«ãªãã·ããŒãŒæšèãã第äºæäœïŒ10
ã100ÎŒgïŒÎŒïŒã50ã100ÎŒïŒç©Žå ããããã«
ïŒâã§ïŒæ©ãããã¯å®€æž©ã§ïŒãïŒæéæŸçœ®ããã
第äºæäœãšããŠãããªãã³åæäœã䜿çšããå Žå
ã«ã¯ããã¬ãŒããPBSã§ããæŽæµåŸãã¢ããžã³
âããªãã³âãã«ãªãã·ããŒãŒïŒ10ÎŒgïŒmlïŒã
50ã100ÎŒïŒç©Žå ãã宀枩ã§30åéæŸçœ®åŸPBS
ã§ããæŽæµããã次ã«åºè³ªæ¶²ãšããŠãABTSåº
質液ã50ã100ÎŒïŒç©Žå ãã宀枩ã§10ã30åé
æŸçœ®ããïŒïŒ SDS溶液50ã100ÎŒïŒç©Žãå ãå
å¿ãåæ¢ãããåç©Žã®OD415å€ã枬å®ãããã®çº
è²åºŠãããè¡æž æ€äœäžã®æåéãç®åºããããã®
ããã«ããŠåŸãããå¥åžžäººè¡æž äžã®æåéãšèºç
æ£è è¡æž äžã®æåéãæ¯èŒããããšã«ãããæ£åžž
å€ã決å®ãããã®æ£åžžå€ãè¶ ãããã®ãèºçéœæ§
ãšããã (6) æå解æ åè¿°ã®é µçŽ å ç«æäœæ³ãå ç«çµç¹ååŠçæè²æ³
ãããã¯è¡æž 蚺ææ³ã®å®æœã«éããŠãæåïŒèºè º
çèæåãèºçå¹é€çŽ°èæ ªãèºççµç¹ïŒããã€ã©
ããããŒãŒïŒneuraminidaseïŒããããã¢ãŒãŒ
ïŒproteaseïŒãªã©ã®é µçŽ ãéãšãŠçŽ é žãªã©ã®è©Šè¬
ã§ååŠçããåŸãåã¯ããŒã³æ§æäœãšåå¿ããã
ãããã®åŠçãããŠããªãå ã®æåãšåã¯ããŒã³
æ§æäœã®åå¿æ§ãšã®å·®ãããæåã®ååŠçæ§ç¶
ïŒåã¯ããŒã³æ§æäœã®èªèããæåéšäœã®ååŠç
æ§ç¶ïŒãæããã«ãããããªãã¡ããã€ã©ããã
ãŒãŒåŠçã«ããæåæ§ãæ¶å€±ããã°ãã·ã¢ã«é ž
ãããããã¢ãŒãŒåŠçã«ããæ¶å€±ããã°èçœè³ª
ãããŸãéãšãŠçŽ é žåŠçã«ããæ¶å€±ããã°ç³é
ããæå決å®åºã«é¢äžããŠãããšæšå®ãããã 以äžæ¬çºæã®å®æœäŸã瀺ãã å®æœäŸ ïŒ (1) æäœç£ç现èã®èª¿è£œ ããæ£åžžèºçµç¹èæåïŒïŒmgèçœè³ªïŒå¹ïŒãã
çåŸ24æé以å ã®æ°çä»BALBïŒïœããŠã¹ã«é
èå æäžãããïŒé±éçµéåŸã®ããŠã¹ã«ããèºè º
çèæç100ÎŒïŒèçœè³ªæç®ïŒïŒå¹ãæ°Žé žåã¢
ã«ãããŠã ã²ã«ïŒmgïŒå¹ãçŸæ¥å³èæ»èã¯ã¯ãã³
ïŒÃ109ïŒå¹ãšãšãã«è ¹è å æäžããã以åŸïŒã
ïŒé±ããã«ãåäžæå100ÎŒgïŒèçœè³ªæç®ïŒïŒå¹
ã§ïŒãïŒåå ç«ããããããå ç«åŠçããããŠã¹
ã®ãã¡ããã®æè¡æž ããããèºè ºç现èãŸãã¯çµ
ç¹ãããã¯ãããã®èæçãšåŒ·ãåå¿ããããŠã¹
ãå ç«ããŠã¹ãšããŠããã®ããŠã¹ãããèŸçŽ°èã
調補ããŠã现èèåã«äŸããã (2) ããŠã¹éªšé«è «çŽ°èã®èª¿è£œ ïŒâã¢ã¶ã°ã¢ãã³èæ§ããŠã¹éªšé«è «çŽ°èæ ªP3
âU1ãæ£åžžå¹å°ã§å¹é€ãã现èèåæã«ïŒÃ107
以äžã®çŽ°èãåŸã现èèåã«èŠªæ ªãšããŠäŸããã (3) ãã€ããªããŒãã®äœè£œ (1)ãš(2)ã§åŸãããèŸçŽ°èãšéªšé«è «çŽ°èãšãïŒïŒ
ïŒã®å²åã§çšããåè¿°ããæ¹åŒã§èåããã
HATå¹å°ã§37âã14æ¥éCO25ïŒ ä»¥äžã§å¹é€ã
ããèå现èãéžæããHTå¹å°ã«å€ããŠããã«
å¹é€ããæããèºè ºçã«å¯ŸããæäœäŸ¡ã®æž¬å®ãã
ãŠã掻æ§ãªç©Žãéžã³ãããã«æ£åžžå¹å°ã«å€ããïŒ
åã¯ããŒãã³ã°ãç¹°ãè¿ããŠãçš®ã ã®æž¬å®æ³ã«ã
ããããæ£åžžçŽ°èãçµç¹ãããã¯ä»ã®çã«å šãå
å¿ãããããèºè ºçã«ç¹ç°çã«åå¿ããåã¯ããŒ
ã³æ§æäœãç£çãããã€ããªããŒãæ ªALCâ186
ãéžæããã ïŒ åã¯ããŒã³æ§æäœã®ç²Ÿè£œ ããªã¹ã¿ã³åŠçããïŒé±ä»€BALBïŒïœéããŠ
ã¹ã«(3)ã§åŸããããã€ããªããŒãæ ªALCâ186ã
ïŒÃ106现èïŒå¹è ¹è å 泚å°ããã10ã21æ¥åŸã«ã
ãã€ããªããŒãã¯è ¹æ°Žçåãããè ¹æ°Žã®ããŸã€ã
ããŠã¹ãããè ¹æ°Žãæ¡åïŒïŒã10mlïŒå¹ïŒããé
å¿åé¢ïŒ3000rpmïŒïŒåïŒããŠåºåœ¢åãé€å»ã
ãã50ïŒ ç¡«é žã¢ã³ã¢ããŠã ã«ãŠå¡©æããPBSã«
NaCl 0.5Mãå ãã液ã§éæããã»ãã¢ã¯ãªã«
S300ïŒãã¢ã«ãã·ã¢ã»ãã¢ã€ã³ã»ã±ãã«ã«ç€Ÿè£œïŒ
ïŒãããã»ããªãŠãŒã 750mlïŒã®ã«ã©ã ã«æµé15
mlïŒhrã§éå¡ãIgMç»åãéã粟補æäœãšããŠçš
ããã (5) ALCâ186ã®ç¹ç°æ§ ãã®ããã«ããŠåŸãããæèºè ºçç¹ç°çåã¯ã
ãŒã³æ§æäœALCâ186ã®åå¿ç¹ç°æ§ã第ïŒè¡šã«ç€º
ããã
ãè¡šã
ïŒïŒ 倧è
žçå¹é€çŽ°èæ ªãšåŒ±ãåå¿
å®æœäŸ ïŒ å®æœäŸïŒã§åŸãããåã¯ããŒã³æ§æäœALCâ
186ãçšããŠãèºè ºççµç¹ã®å ç«çµç¹ååŠçæè²
ãè¡ã€ãã10äŸã®èºè ºçæ£è æåºèºè ºçãã©ãã€
ã³å åãããã¯åçã«ã€ããŠæ€èšããçµæãïŒäŸ
ã§ç现èã匷ãæãŸã€ãã以äžã®çµæããã
ALCâ186ãçšããå ç«çµç¹ååŠæè²ã«ãããèº
è ºçã®ç ç蚺æãå¯èœã§ãã€ãã å®æœäŸ ïŒ 96ç©ŽEIAçšãã¬ãŒãããããŒã»ã©ãã©ããªãŒãº
ïŒFlow LaboratoriesïŒç€Ÿè£œãã«ãALCâ186
ïŒ10ÎŒïŒmlïŒã50ÎŒïŒç©Žå ããïŒâã§ïŒæ©æŸçœ®
åŸãPBSã§æŽæµããïŒïŒ BSAâPBS200ÎŒïŒç©Ž
å ãïŒæ©æŸçœ®ããPBSã§ããæŽæµãããã¬ãŒã
ã«ãå¥åº·äººè¡æž ïŒ77æ€äœïŒããã³èºçæ£è è¡æž
ïŒ92æ€äœïŒãïŒååžéããŠ40ÎŒïŒç©Žå ããïŒâ
ã§ïŒæ©æŸçœ®åŸãPBSã§ããæŽæµããã次ã«ã第
äºæäœãšããŠãããªãã³åæèºçã¢ãã¯ããŒãã«
æäœALCâ186ïŒ10ÎŒïŒmlïŒã100ÎŒïŒç©Žå ãã
ïŒâã§ïŒæ©æŸçœ®ããPBSã§ããæŽæµããåŸãã¢
ããžã³âããªãã³âãã«ãªãã·ããŒãŒããã¯ããŒ
ã«ïŒVECTORïŒç€Ÿè£œãïŒ10ÎŒgïŒmlïŒ100ÎŒïŒç©Ž
å ãã宀枩ã§ïŒæéæŸçœ®ããåŸãPBSã§æŽæµã
ãã次ã«ABTSåºè³ªæ¶²ã100ÎŒïŒç©Žå ãã宀枩
ã§30åéåå¿ãããïŒïŒ SDS溶液100ÎŒïŒç©Žã
å ãåå¿ãåæ¢ãããåç©Žã®çºè²ãåžå å 床èš
ïŒOD415ïŒã§æž¬å®ããããã®çµæã第ïŒå³ã«ç€ºã
ãæ§ã«ãå¥åº·äººè¡æž ã§ã¯ãOD415ã0.35ãããã
éœæ§äŸã¯77äŸäžïŒäŸãããªãã€ãããèºè ºçæ£è
è¡æž ã§ã¯ãOD415ã0.35ããããéœæ§äŸã33äŸäž
16äŸãã€ãããã®ããšãããæ¬æäœãçšããè¡æž
蚺ææ³ã«ããã48ïŒ ã®ç¢ºçã§èºè ºçæ£è ãèŠåºã
ããšãå¯èœãããããšãããããèºæå¹³äžç®çæ£
è è¡æž ã§ã¯ãOD415ã0.35ããããéœæ§äŸãã33
äŸäžïŒäŸïŒïŒïŒ ïŒãèºå°çŽ°èçæ£è è¡æž ã§ã¯ã22
äŸäžïŒäŸïŒïŒïŒ ïŒãèºå€§çŽ°èçæ£è è¡æž ã§ã¯ãïŒ
äŸäžïŒäŸïŒïŒïŒ ïŒã§ãã€ãããèºè¯æ§çŸæ£æ£è è¡
æž ã§ã¯16äŸäžïŒäŸïŒïŒïŒ ïŒïŒãšå šãéœæ§äŸã¯ãªã
ã€ãã ãŸããèºè ºçæ£è è¡æž ããããããããšã第ïŒ
å³ã«ç€ºãããšããã¹ããŒãžã§ã¯65ïŒ ïŒ20äŸäž13
äŸïŒã§éœæ§ãšãªã€ãããã®çµæã¯ãæ¬æäœã«ãã
è¡æž 蚺æãèºè ºçã®ã¢ãã¿ãªã³ã°ã«æå¹ã§ããã
ãšã瀺ããŠããã å®æœäŸ ïŒ åã¯ããŒã³æ§æäœALCâ186ãèªèããæåã
解æããããã«ãèºè ºççµç¹ã®èæåãäžèšåçš®
é µçŽ ããã³è©Šè¬ã§åŠçããåŸALCâ186ãšã®åå¿
æ§ã調ã¹ãã é µçŽ ããã³è©Šè¬ ããªãã·ã³ïŒGIBCO瀟補 2.5ïŒ æº¶æ¶²ïŒ
PBSäž 0.25ïŒ ãã€ã©ããããŒãŒïŒããŒãªã³ã¬ãŒã»ãã³ãã€ã
瀟補ïŒ
0.1Mé ¢é žãããã¢ãŒïŒPH4.5ïŒâ3mMCaCl2äž
0.1UïŒml αââãã³ã·ããŒãŒïŒããŒãªã³ã¬ãŒã»ãã€ã
ã€ã 瀟補ïŒ
0.1Mãªã³é žãããã¢ïŒPH6.3ïŒäž0.1UïŒml ãããã¢ãŒãŒïŒã·ã°ã瀟補ïŒ
0.1Mãªã³é žãããã¢ãŒïŒPH7.2ïŒäž10UïŒml NaIO4ïŒåå çŽè¬ç€Ÿè£œïŒ PBSäž50mM èºè ºççµç¹ã®èæåïŒèçœé100ÎŒgïŒmlïŒã
50ÎŒïŒç©Žãã€ãEIAçšãã¬ãŒãããªã³ãã
ïŒLinbroïŒç€Ÿè£œãã«å泚ããïŒâã§ïŒæ©æŸçœ®åŸã
PBSã§ïŒåæŽæµããïŒïŒ BSAâPBSã200ÎŒïŒ
ç©Žå泚ãã30åéãïŒæé宀枩ã§æŸçœ®ããPBS
ã§ïŒåæŽæµåŸãäžèšé µçŽ 液ãŸãã¯è©Šè¬æ¶²ã50ÎŒ
ïŒç©Žå泚ãã37âã§ïŒæéåå¿ããããã€ãã§
PBSã§ïŒåæŽæµããåã¯ããŒã³æ§æäœALCâ186
ïŒ10ÎŒgïŒmlïŒã50ÎŒïŒç©Žå泚ããïŒâã§ïŒæ©æŸ
眮ããã Tweenâ20âPBSïŒTween 20ã¯åå çŽè¬å·¥æ¥
瀟補ïŒã§ïŒåæŽæµåŸãããŒãªãã·ããŒãŒæšèæâ
ããŠã¹IgGïŒ400ååžé液ïŒã50ÎŒïŒç©Žå ãã宀
æž©ã§ïŒæéåå¿åŸãTweenâ20âPBSã§ïŒåæŽ
æµããABTSåºè³ª100ÎŒãå ãã30åéåå¿åŸã
415nmã«ãããåžå 床ã枬å®ããã æåæ§ã¯ã第ïŒå³ã«ç€ºãããšãããéãšãŠçŽ é ž
ïŒNaIO4ïŒããã€ã©ããããŒãŒããããã¢ããŒãŒåŠ
çã«ããå®å šã«æ¶å€±ããããã®çµæãããåã¯ã
ãŒã³æ§æäœALCâ186ã¯ã·ã¢ã«é žåãããç³èçœ
質ãèªèããŠãããã®ãšæšå®ãããã
å®æœäŸ ïŒ å®æœäŸïŒã§åŸãããåã¯ããŒã³æ§æäœALCâ
186ãçšããŠãèºè ºççµç¹ã®å ç«çµç¹ååŠçæè²
ãè¡ã€ãã10äŸã®èºè ºçæ£è æåºèºè ºçãã©ãã€
ã³å åãããã¯åçã«ã€ããŠæ€èšããçµæãïŒäŸ
ã§ç现èã匷ãæãŸã€ãã以äžã®çµæããã
ALCâ186ãçšããå ç«çµç¹ååŠæè²ã«ãããèº
è ºçã®ç ç蚺æãå¯èœã§ãã€ãã å®æœäŸ ïŒ 96ç©ŽEIAçšãã¬ãŒãããããŒã»ã©ãã©ããªãŒãº
ïŒFlow LaboratoriesïŒç€Ÿè£œãã«ãALCâ186
ïŒ10ÎŒïŒmlïŒã50ÎŒïŒç©Žå ããïŒâã§ïŒæ©æŸçœ®
åŸãPBSã§æŽæµããïŒïŒ BSAâPBS200ÎŒïŒç©Ž
å ãïŒæ©æŸçœ®ããPBSã§ããæŽæµãããã¬ãŒã
ã«ãå¥åº·äººè¡æž ïŒ77æ€äœïŒããã³èºçæ£è è¡æž
ïŒ92æ€äœïŒãïŒååžéããŠ40ÎŒïŒç©Žå ããïŒâ
ã§ïŒæ©æŸçœ®åŸãPBSã§ããæŽæµããã次ã«ã第
äºæäœãšããŠãããªãã³åæèºçã¢ãã¯ããŒãã«
æäœALCâ186ïŒ10ÎŒïŒmlïŒã100ÎŒïŒç©Žå ãã
ïŒâã§ïŒæ©æŸçœ®ããPBSã§ããæŽæµããåŸãã¢
ããžã³âããªãã³âãã«ãªãã·ããŒãŒããã¯ããŒ
ã«ïŒVECTORïŒç€Ÿè£œãïŒ10ÎŒgïŒmlïŒ100ÎŒïŒç©Ž
å ãã宀枩ã§ïŒæéæŸçœ®ããåŸãPBSã§æŽæµã
ãã次ã«ABTSåºè³ªæ¶²ã100ÎŒïŒç©Žå ãã宀枩
ã§30åéåå¿ãããïŒïŒ SDS溶液100ÎŒïŒç©Žã
å ãåå¿ãåæ¢ãããåç©Žã®çºè²ãåžå å 床èš
ïŒOD415ïŒã§æž¬å®ããããã®çµæã第ïŒå³ã«ç€ºã
ãæ§ã«ãå¥åº·äººè¡æž ã§ã¯ãOD415ã0.35ãããã
éœæ§äŸã¯77äŸäžïŒäŸãããªãã€ãããèºè ºçæ£è
è¡æž ã§ã¯ãOD415ã0.35ããããéœæ§äŸã33äŸäž
16äŸãã€ãããã®ããšãããæ¬æäœãçšããè¡æž
蚺ææ³ã«ããã48ïŒ ã®ç¢ºçã§èºè ºçæ£è ãèŠåºã
ããšãå¯èœãããããšãããããèºæå¹³äžç®çæ£
è è¡æž ã§ã¯ãOD415ã0.35ããããéœæ§äŸãã33
äŸäžïŒäŸïŒïŒïŒ ïŒãèºå°çŽ°èçæ£è è¡æž ã§ã¯ã22
äŸäžïŒäŸïŒïŒïŒ ïŒãèºå€§çŽ°èçæ£è è¡æž ã§ã¯ãïŒ
äŸäžïŒäŸïŒïŒïŒ ïŒã§ãã€ãããèºè¯æ§çŸæ£æ£è è¡
æž ã§ã¯16äŸäžïŒäŸïŒïŒïŒ ïŒïŒãšå šãéœæ§äŸã¯ãªã
ã€ãã ãŸããèºè ºçæ£è è¡æž ããããããããšã第ïŒ
å³ã«ç€ºãããšããã¹ããŒãžã§ã¯65ïŒ ïŒ20äŸäž13
äŸïŒã§éœæ§ãšãªã€ãããã®çµæã¯ãæ¬æäœã«ãã
è¡æž 蚺æãèºè ºçã®ã¢ãã¿ãªã³ã°ã«æå¹ã§ããã
ãšã瀺ããŠããã å®æœäŸ ïŒ åã¯ããŒã³æ§æäœALCâ186ãèªèããæåã
解æããããã«ãèºè ºççµç¹ã®èæåãäžèšåçš®
é µçŽ ããã³è©Šè¬ã§åŠçããåŸALCâ186ãšã®åå¿
æ§ã調ã¹ãã é µçŽ ããã³è©Šè¬ ããªãã·ã³ïŒGIBCO瀟補 2.5ïŒ æº¶æ¶²ïŒ
PBSäž 0.25ïŒ ãã€ã©ããããŒãŒïŒããŒãªã³ã¬ãŒã»ãã³ãã€ã
瀟補ïŒ
0.1Mé ¢é žãããã¢ãŒïŒPH4.5ïŒâ3mMCaCl2äž
0.1UïŒml αââãã³ã·ããŒãŒïŒããŒãªã³ã¬ãŒã»ãã€ã
ã€ã 瀟補ïŒ
0.1Mãªã³é žãããã¢ïŒPH6.3ïŒäž0.1UïŒml ãããã¢ãŒãŒïŒã·ã°ã瀟補ïŒ
0.1Mãªã³é žãããã¢ãŒïŒPH7.2ïŒäž10UïŒml NaIO4ïŒåå çŽè¬ç€Ÿè£œïŒ PBSäž50mM èºè ºççµç¹ã®èæåïŒèçœé100ÎŒgïŒmlïŒã
50ÎŒïŒç©Žãã€ãEIAçšãã¬ãŒãããªã³ãã
ïŒLinbroïŒç€Ÿè£œãã«å泚ããïŒâã§ïŒæ©æŸçœ®åŸã
PBSã§ïŒåæŽæµããïŒïŒ BSAâPBSã200ÎŒïŒ
ç©Žå泚ãã30åéãïŒæé宀枩ã§æŸçœ®ããPBS
ã§ïŒåæŽæµåŸãäžèšé µçŽ 液ãŸãã¯è©Šè¬æ¶²ã50ÎŒ
ïŒç©Žå泚ãã37âã§ïŒæéåå¿ããããã€ãã§
PBSã§ïŒåæŽæµããåã¯ããŒã³æ§æäœALCâ186
ïŒ10ÎŒgïŒmlïŒã50ÎŒïŒç©Žå泚ããïŒâã§ïŒæ©æŸ
眮ããã Tweenâ20âPBSïŒTween 20ã¯åå çŽè¬å·¥æ¥
瀟補ïŒã§ïŒåæŽæµåŸãããŒãªãã·ããŒãŒæšèæâ
ããŠã¹IgGïŒ400ååžé液ïŒã50ÎŒïŒç©Žå ãã宀
æž©ã§ïŒæéåå¿åŸãTweenâ20âPBSã§ïŒåæŽ
æµããABTSåºè³ª100ÎŒãå ãã30åéåå¿åŸã
415nmã«ãããåžå 床ã枬å®ããã æåæ§ã¯ã第ïŒå³ã«ç€ºãããšãããéãšãŠçŽ é ž
ïŒNaIO4ïŒããã€ã©ããããŒãŒããããã¢ããŒãŒåŠ
çã«ããå®å šã«æ¶å€±ããããã®çµæãããåã¯ã
ãŒã³æ§æäœALCâ186ã¯ã·ã¢ã«é žåãããç³èçœ
質ãèªèããŠãããã®ãšæšå®ãããã
第ïŒå³ã¯ãåã¯ããŒã³æ§æäœALCâ186ã«ãã
èºè ºçã®è¡æž 蚺æã®çµæã瀺ãã第ïŒå³ã¯ãåã¯
ããŒã³æ§æäœALCâ186ã«ããèºè ºçã®è¡æž 蚺æ
ã«ãããã¹ããŒãžã®åœ±é¿ã瀺ãã第ïŒå³ã¯ãèºè º
ççµç¹ã®èæåã®åçš®é µçŽ ãè©Šè¬åŠçã«ããåã¯
ããŒã³æ§æäœALCâ186ãšã®åå¿æ§ã®æ¶é·ã瀺
ãã âã¯ãã€ã©ããããŒãŒ0.1UïŒmlãâ³ã¯Î±â
âãã³ã·ããŒãŒ0.1UïŒmlãâ¡ã¯ããªãã·ã³0.25ã
â ã¯ãããã¢ãŒãŒ10UïŒmlããã¯NaIO450mMã®
åŠçã瀺ããÃã¯ç¡åŠçã瀺ãã
èºè ºçã®è¡æž 蚺æã®çµæã瀺ãã第ïŒå³ã¯ãåã¯
ããŒã³æ§æäœALCâ186ã«ããèºè ºçã®è¡æž 蚺æ
ã«ãããã¹ããŒãžã®åœ±é¿ã瀺ãã第ïŒå³ã¯ãèºè º
ççµç¹ã®èæåã®åçš®é µçŽ ãè©Šè¬åŠçã«ããåã¯
ããŒã³æ§æäœALCâ186ãšã®åå¿æ§ã®æ¶é·ã瀺
ãã âã¯ãã€ã©ããããŒãŒ0.1UïŒmlãâ³ã¯Î±â
âãã³ã·ããŒãŒ0.1UïŒmlãâ¡ã¯ããªãã·ã³0.25ã
â ã¯ãããã¢ãŒãŒ10UïŒmlããã¯NaIO450mMã®
åŠçã瀺ããÃã¯ç¡åŠçã瀺ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ããèºè ºçã®çŽ°èããã³çµç¹ãšåå¿ãããã
èºè ºç以å€ã®èºçããã³ããæ£åžžèºã®çŽ°èããã³
çµç¹ãšã¯åå¿ãããã·ã¢ã«é žåãããç³èçœè³ªãŸ
ãã¯ç³è質ãæåãšããŠèªèããåã¯ããŒã³æ§æ
äœã ïŒ è©²åã¯ããŒã³æ§æäœããã€ããªããŒã现èæ ª
ALCâ186ïŒNCACC 85082903ïŒããçç£ããã
ããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å
ã¯ããŒã³æ§æäœã ïŒ è©²åã¯ããŒã³æ§æäœãIgMã¯ã©ã¹ã«å±ããã
ãšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åã¯
ããŒã³æ§æäœã ïŒ ããèºè ºçã®çŽ°èããã³çµç¹ãšåå¿ãããã
èºè ºç以å€ã®èºçããã³ããæ£åžžèºã®çŽ°èããã³
çµç¹ãšã¯åå¿ãããã·ã¢ã«é žåãããç³èçœè³ªãŸ
ãã¯ç³è質ãæåãšããŠèªèããåã¯ããŒã³æ§æ
äœãçšããå ç«çµç¹ååŠçæè²æ³ã ïŒ ããèºè ºçã®çŽ°èããã³çµç¹ãšåå¿ãããã
èºè ºç以å€ã®èºçããã³ããæ£åžžèºã®çŽ°èããã³
çµç¹ãšã¯åå¿ãããã·ã¢ã«é žåãããç³èçœè³ªãŸ
ãã¯ç³è質ãæåãšããŠèªèããåã¯ããŒã³æ§æ
äœãçšãããµã³ãã€ããæ¹åŒã«ããé µçŽ å ç«æž¬å®
æ³ãŸãã¯ã©ãžãªã€ã ãã¢ãã»ã€ã«ããããè¡æž äž
ã®èºè ºçæåãæ€åºããæ¹æ³ã
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60225327A JPS6283898A (ja) | 1985-10-09 | 1985-10-09 | æããèºè ºçç¹ç°çåã¯ãâã³æ§æäœ |
CA000520126A CA1306707C (en) | 1985-10-09 | 1986-10-08 | Anti-human pulmonary adenocarcinoma specific monoclonal antibody |
EP19860114025 EP0218257B1 (en) | 1985-10-09 | 1986-10-09 | Anti-human pulmonary adenocarcinoma specific monoclonal antibody |
DE8686114025T DE3684857D1 (de) | 1985-10-09 | 1986-10-09 | Spezifischer monoklonaler antikoerper gegen menschliches lungenadenokarzinom. |
US08/194,633 US5552291A (en) | 1985-10-09 | 1994-02-10 | Anti-human pulmonary adenocarcinoma specific monoclonal antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60225327A JPS6283898A (ja) | 1985-10-09 | 1985-10-09 | æããèºè ºçç¹ç°çåã¯ãâã³æ§æäœ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6283898A JPS6283898A (ja) | 1987-04-17 |
JPH0570434B2 true JPH0570434B2 (ja) | 1993-10-05 |
Family
ID=16827613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60225327A Granted JPS6283898A (ja) | 1985-10-09 | 1985-10-09 | æããèºè ºçç¹ç°çåã¯ãâã³æ§æäœ |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0218257B1 (ja) |
JP (1) | JPS6283898A (ja) |
CA (1) | CA1306707C (ja) |
DE (1) | DE3684857D1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61258173A (ja) * | 1985-05-10 | 1986-11-15 | Akira Taniuchi | ã¢ãã¯ãâãã«æäœããã³ãã®è£œæ³ãªãã³ã«çšé |
JPH0813840B2 (ja) * | 1987-03-31 | 1996-02-14 | ååéé µå·¥æ¥æ ªåŒäŒç€Ÿ | æããèºè ºçåã¯ãâã³æ§æäœ |
US5580740A (en) * | 1988-03-28 | 1996-12-03 | Kyowa Hakko Kogyo Co., Ltd. | Antihuman pulmonary adenocarcinoma monoclonal antibody |
US5242824A (en) * | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
IL95999A0 (en) * | 1989-10-20 | 1991-07-18 | Hybritech Inc | Tumor-associated antigen |
US5250297A (en) * | 1989-10-20 | 1993-10-05 | Hybritech Incorporated | Tumor-associated antigen, antibodies, compositions and uses therefor |
BR9106995A (pt) * | 1990-11-23 | 1993-08-24 | Gen Hospital Corp | Inibicao de interacoes proteina-carboidrato com adesao celular |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210867A (en) * | 1984-01-31 | 1989-01-06 | Litton Bionetics Inc | Tumour-specific monoclonal antibodies, production thereof and use |
JPS60190722A (ja) * | 1984-03-12 | 1985-09-28 | Kyowa Hakko Kogyo Co Ltd | æããèºçåã¯ãâã³æ§æäœ |
JPS60190721A (ja) * | 1984-03-12 | 1985-09-28 | Kyowa Hakko Kogyo Co Ltd | æè «çç¹ç°çåã¯ãâã³æ§æäœã®è£œé æ³ |
-
1985
- 1985-10-09 JP JP60225327A patent/JPS6283898A/ja active Granted
-
1986
- 1986-10-08 CA CA000520126A patent/CA1306707C/en not_active Expired - Lifetime
- 1986-10-09 DE DE8686114025T patent/DE3684857D1/de not_active Expired - Lifetime
- 1986-10-09 EP EP19860114025 patent/EP0218257B1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CA1306707C (en) | 1992-08-25 |
DE3684857D1 (de) | 1992-05-21 |
JPS6283898A (ja) | 1987-04-17 |
EP0218257A2 (en) | 1987-04-15 |
EP0218257A3 (en) | 1989-08-02 |
EP0218257B1 (en) | 1992-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6319561A (ja) | æããèºçåã¯ãâã³æ§æäœ | |
DK172440B1 (da) | Monoklonale antistoffer og derivater deraf, fremgangsmåde til deres fremstilling, hybridomacellelinie og fremgangsmåde til | |
JPS63279784A (ja) | æ°ã ãã³ãšãããŒãã«å¯Ÿããåã¯ããŒã³æ§æäœãçæãããã€ããªããŒã | |
JPS60190721A (ja) | æè «çç¹ç°çåã¯ãâã³æ§æäœã®è£œé æ³ | |
EP0171083B1 (en) | Monoclonal antibody, process for preparing same, reagent for detecting cancer antigen containing the monoclonal antibody and process for preparing same | |
JPH0570434B2 (ja) | ||
JPS6344895A (ja) | æã¢ããã€ãïœèçœè³ªåã¯ãâã³æ§æäœ | |
CA1320460C (en) | Anti-human gastric cancer monoclonal antibody | |
JPS60190722A (ja) | æããèºçåã¯ãâã³æ§æäœ | |
AU690756B2 (en) | Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof | |
JPS63157995A (ja) | æããå€§è žçåã¯ãâã³æ§æäœïœïœïœâïŒïŒïŒ | |
JPH04304897A (ja) | æã€ãã£ãªã¿ã€ãã¢ãã¯ããŒãã«æäœ | |
JPS62207298A (ja) | æããèçåã¯ãâã³æ§æäœ | |
US4962032A (en) | Anti-lafora body monoclonal antibody | |
JPH02135098A (ja) | âã°ãªã³ãªã«åïœïœâïŒãèªèããã¢ãã¯ããŒãã«æäœåã³ãããç£çãããã€ããªããŒã | |
EP0285143B1 (en) | Antihuman pulmonary adenocarcinoma monoclonal antibody | |
JPH0213393A (ja) | æããèºè ºçåã¯ããŒã³æ§æäœ | |
JPS6280558A (ja) | æããèºè ºçç¹ç°çåã¯ãâã³æ§æäœ | |
JPS61183300A (ja) | ã¢ãã¯ãâãã«æäœ | |
JPS61250000A (ja) | ã¢ãã¯ãâãã«æäœ | |
JPH01277498A (ja) | æããèçã¢ãã¯ããŒãã«æäœïœïœïœâïŒïŒ | |
JPH0787798B2 (ja) | ã¢ãã¯ãâãã«æäœã®è£œé æ¹æ³ | |
JPS61249999A (ja) | ã¢ãã¯ãâãã«æäœ | |
JPH02109993A (ja) | ãã现èèäžã®èçœæåã«å¯Ÿããã¢ãã¯ããŒãã«æäœãå¹ççã«äœæããæ¹æ³ | |
JPH06102038B2 (ja) | ã¢ãã¯ãâãã«æäœ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |